Patients who carries GAS5 rs145204276 ins/del or del/del showed decreased risk of clinical locally advanced disease (OR=0.513; 95% CI=0.286-0.923, p=0.024), pathological lymph node metastasis disease (OR=0.462; 95% CI=0.225-0.946, p=0.032) and lymphovascular invasion (OR=0.521; 95% CI=0.292-0.927, p=0.025) comparing to with genotype ins/ins. This evidence concerns the gene GAS5 and glycogen storage disease VI.